428 Randomized, double-blind, placebo-controlled study of efficacy and safety of secukinumab to treat adults with ichthyoses

Therapy for congenital ichthyoses remains unsatisfactory. Ichthyoses, characterized by barrier impairment with cutaneous erythema and scaling, share Th17 immune skewing, as in psoriasis, leading us to hypothesize that targeting IL-17A could reduce ichthyosis severity. Adults with ichthyosis were randomized 1:1 to receive 300 mg of secukinumab, an IL-17A inhibitor, or placebo every 4 wks in a 16-wk dual-center, double-blind trial, followed by...